Article |
By Dan Bowles, Mike Johnson, and Brian Swierenga,Cambrex
To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.
Choosing the right tag is essential to getting the purity, solubility, and protein quality your application needs. Learn how to prepare a recombinant protein in the quantity and quality you need.
Discover an approach to wastewater treatment that reduces the environmental impact of small molecules production and introduces advanced treatment methodologies to avoid wastewater incineration.
The pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding, and strategies to improve the performance of IB processes.